arrow
B

Bernardo A. Mainou

us centers for disease control and prevention
H指数:25
被引数:2,428

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity and safety of Sabin inactivated poliovirus vaccine in a sequential schedule with bivalent oral poliovirus vaccine in Nepal: a single-centre, double-blind, randomised, controlled, non-inferiority trial

Sabin灭活脊髓灰质炎疫苗与双价口服脊髓灰质炎疫苗在序贯接种方案中的免疫原性和安全性:一项单中心、双盲、随机、对照、非劣效性试验

2026-11-050
OA
Effect of Inactivated Poliovirus Vaccine on Nasal Mucosal Immunity and Pharyngeal Shedding Following Novel Oral Poliovirus Vaccine Type 2 Challenge: A Randomized, Open-label Trial

灭活脊髓灰质炎疫苗对新型口服脊髓灰质炎疫苗2型挑战后鼻黏膜免疫和咽部排毒的影响:一项随机、开放标签试验

2026-08-180
OAAI
Immunogenicity of type 2 novel oral poliovirus vaccine administered in outbreak response, Kenya 2023: an observational cohort study

2023年肯尼亚疫情应对中接种的新型口服脊髓灰质炎病毒疫苗2型的免疫原性:一项观察性队列研究

Vaccine
IF3.5
2026-08-010
PRE
Am80-lipid nanoparticles serve as an enteric mucosal adjuvant following parenteral immunization with inactivated polio vaccine

口服免疫后,Am80-脂质纳米颗粒作为灭活脊髓灰质炎疫苗的肠黏膜佐剂

2026-06-030
OA
Intramuscular versus intradermal administration of fractional dose inactivated poliovirus vaccine in Mozambique, 2020–2022: an, open-label, non-inferiority, randomised, controlled phase 2 trial

肌内注射与皮内注射分剂量灭活脊髓灰质炎病毒疫苗在莫桑比克,2020–2022年:一项开放标签、非劣效性、随机对照2期试验

2025-12-030
OAAI
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns

Godin, A.; Brickley, E.B.; Connor, R.I.; Wieland-Alter, W.F.; Weiner, J.A.; Ackerman, M.E.; Modlin, J.F.; Sajjad, O.M.; Arita, M.; Gast, C.; 等. 健康新生儿对新型口服脊髓灰质炎病毒疫苗2型的肠道黏膜免疫反应。Clin. Infect. Dis. 2025, ciaf484. [Google Scholar] [CrossRef]

2025-09-050
OAAI
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial

新型1型与3型口服减毒脊髓灰质炎疫苗在健康美国成年人中的安全性与免疫原性:一项首次人体、观察者设盲、多中心、第1期随机对照试验

2025-08-130
OAAI
Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022

新型口服脊髓灰质炎病毒2型疫苗接种运动的影响:尼日利亚2022年血清流行病学调查

VACCINE
IF3.5
2025-04-010
OAAI
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort study
2024-04-011
OAAI
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial
LANCET
IF88.5
2024-03-015
OAAI
Poliovirus serological assay after the cVDPV1 outbreak in Papua New Guinea: a cross-sectional study from 2020 to 2021

巴布亚新几内亚cVDPV1暴发后脊髓灰质炎病毒血清学检测: 一项2020年2021年的横断面研究

2024-03-011
OAAI
Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial
2023-09-0113
PRE
Poliovirus antibodies following two rounds of campaigns with atype 2 novel oral poliovirus vaccine in Liberia: a clustered, population-based seroprevalence survey

在利比里亚使用2型新型口服脊髓灰质炎病毒疫苗进行两轮运动后的脊髓灰质炎病毒抗体: 一项基于人群的分组血清阳性率调查

2023-06-0111
OAAI